Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NVCT vs MNOV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MNOV Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–3 Matrix Metrics)

MNOV Overall Winner 6-Pillar Tally: NVCT 0 – 5 MNOV (1 Tie) Matrix Metrics: NVCT 3 – 6 MNOV

As of Nov 20, 2026, Medicinova, Inc. (MNOV) is the stronger overall head-to-head candidate over Nuvectis Pharma, Inc. (NVCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVCT carries a Unified Composite Score of 48.4/100 (HOLD) at $19.39 (N/M Forward P/E, 0.0% operating margin), whereas MNOV carries 50.2/100 (HOLD) at $1.31 (8.5x Forward P/E, -1232.2% operating margin).

  • Technical & Structure Timing Caution: NVCT is currently in a Breakdown options structure phase (RSI 47.4); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVCT vs MNOV
NVCT NASDAQ
Nuvectis Pharma, Inc. Common Stock
Pharmaceutical Preparations
$19.39
-2.27% 1D
Market Cap $682.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 80% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 34.0 Fund 49.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $19.47 · SMA50: $20.21
MNOV NASDAQ Head-to-Head Winner
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
TTM Revenue $935,717
Forward P/E 8.5x
Beta / 30D Vol 0.59β · 38% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.5%), weak momentum, RSI 36
RSI-14: 36.4 · SMA20: $1.40 · SMA50: $1.74

6-Pillar Scorecard Institutional Category Breakdown (NVCT 0 – 5 MNOV)

Columns: Metric · NVCT · MNOV
1. Valuation Multiples MNOV
Forward P/E N/M 8.5x
Trailing P/E N/M 8.5x
PEG Ratio N/M N/M
EV / Revenue N/M 42.5x
2. Growth & Scale MNOV
Revenue Growth (YoY) +0.0% +12.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $935,717
Market Cap $682.3M $65.1M
3. Profitability & Quality MNOV
Gross Margin N/A 42.2%
Operating Margin 0.0% -1232.2%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -67.0% -24.8%
4. Balance Sheet & Cash Flow MNOV
Cash Generation (TTM) -$40M -$9.1M
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.68 Book/Sh · -67.0% ROE $25M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MNOV
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 106.9% (16th %ile) 140.1% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVCT (3) vs MNOV (6)
Institutional Metric NVCT MNOV Criterion Row Edge
Market Capitalization
Scale
$682.3M $65.1M Larger Scale NVCT
Trailing P/E Ratio
Valuation
N/M 8.5x Lower Multiple MNOV
Forward P/E Ratio
Valuation
N/M 8.5x Lower Multiple MNOV
Revenue Growth (YoY)
Growth
+0.0% +12.4% Higher Growth MNOV
Operating Margin (TTM)
Profitability
0.0% -1232.2% Higher Margin NVCT
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-67.0% -24.8% Higher ROE MNOV
52-Week Range Position
Momentum
58% ($6–$29) 3% ($1–$4) Stronger Trend NVCT
Beta / 30D Volatility
Risk Regime
0.71β · 80% Vol 0.59β · 38% Vol Lower Realized Risk MNOV
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 50.2 / 100 (HOLD) Higher Composite MNOV
Trailing 12M Revenue (USD)
Operating Scale
N/A $935,717 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 42.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 42.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$40M ($3.68 Book/Sh · -67.0% ROE) -$9.1M ($25M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MNOV +0.09 pp
NVCT: -7.18% · MNOV: -7.09%
3M Horizon MNOV +4.39 pp
NVCT: -18.77% · MNOV: -14.38%
6M Horizon NVCT +93.77 pp
NVCT: +87.34% · MNOV: -6.43%
1Y Horizon NVCT +233.18 pp
NVCT: +224.79% · MNOV: -8.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVCT vs MNOV. Trailing 12-month operating profitability (NVCT 0.0% vs MNOV -1232.2%) and valuation multiples (NVCT N/M vs MNOV 8.5x Forward P/E) are benchmarked directly in Pillar 4 below.

NVCT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-67.0% · N/M
MNOV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$935,717
Gross Margin42.2%
Op. Margin-1232.2%
ROE / Fwd P/E-24.8% · 8.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVCT BREAKDOWN
102d in phase · OBV NEUTRAL
Current IV 106.9%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact NVCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 140.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVCT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $682.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MNOV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $65.1M market capitalization and -1232.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NVCT vs MNOV Key Questions & Quantitative Answers

As of Nov 20, 2026, Medicinova, Inc. (MNOV) is the stronger overall head-to-head candidate over Nuvectis Pharma, Inc. (NVCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVCT carries a Unified Composite Score of 48.4/100 (HOLD) at $19.39 (N/M Forward P/E, 0.0% operating margin), whereas MNOV carries 50.2/100 (HOLD) at $1.31 (8.5x Forward P/E, -1232.2% operating margin). Technical & Structure Timing Caution: NVCT is currently in a Breakdown options structure phase (RSI 47.4); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MNOV leads the Growth & Scale pillar: NVCT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MNOV at +12.4% YoY revenue growth and +0.0% YoY earnings growth on $935,717 TTM revenue (42.2% gross margin, -1232.2% operating margin). On trailing 12-month operating scale, NVCT generates N/A in USD-normalized revenue versus $935,717 for MNOV. In operating R&D and SG&A reinvestment, NVCT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MNOV.

MNOV screens cheaper on headline valuation multiples. NVCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MNOV trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 42.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVCT (-67.0% ROE) versus MNOV (-24.8% ROE) capital efficiency.

In options market volatility and institutional positioning, NVCT carries 106.9% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.71β · 80% Vol realized risk). By comparison, MNOV carries 140.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.